Following a strong run in November, global equity markets saw a sharp reversal in sentiment late in the month on the back of fears around the discovery of a new, potentially more contagious strain of COVID-19, named Omicron. However, it’s early days and a lot still needs to be discovered about this new variant. As we approach 2022, understanding the potential implications of Omicron on global growth, interest rates and company earnings will be key. With this in mind, here’s ANZ Investments’ latest Month Ahead.
The month ahead: December 2021